March 13, 2019 admin

Daxor Corporation to Showcase Reduction in Mortality and Hospital Readmissions with BVA-100™ Guided-Care at the Annual Meeting of the American College of Cardiology Expo 2019

NEW YORK – March 13, 2019 – Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at the Annual Meeting of the American College of Cardiology Expo 2019 being held at the Ernest N. Morial Convention Center in New Orleans, LA from March 16-18th.   

“The ACC19 Expo is the largest gathering of innovative cardiovascular products and services shown under one roof.  This meeting is an excellent opportunity to generate awareness and educate more hospitals and cardiologists about the significant benefits of direct and objective measurement of intravascular blood volume, red blood cell volume and plasma volume via a simple blood test with the BVA-100® Blood Volume Analyzer.  We are looking forward to sharing with leaders in the field how use of this unique technology to guide heart failure treatment has been proven to reduce heart failure 30-day mortality by 82%, 30-day readmissions by 56%, and 1-year mortality by 86% in a peer-reviewed study published in the Journal of the American College of Cardiology – Heart Failure,” said Kathryn Kornafel, VP of Marketing.

The Company will be located at booth #1103 in the main exhibition hall.

About Daxor Corporation

Daxor Corporation is an innovative medical instrumentation and biotechnology company.  We manufacture the BVA-100 Blood Volume Analyzer, the first instrument cleared by the FDA to provide rapid direct measurement of a patient’s blood volume.  We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions.  It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.  Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic into standard clinical practice. For more information please visit our website at

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.  Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC.  Forward-looking statements speak only as of the date when made.  Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner